ActiQs / Forskning

PUBLIKATIONSREGISTRET

Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för afatinib. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

22 träffar

Bibliografisk träff 2013-12-01

Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours.

Wind S, Schmid M, Erhardt J, Goeldner RG, Stopfer P.

Clin Pharmacokinet · clinical trial, phase ii; research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s40262-013-0091-4

Bibliografisk träff 2013-10-02

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors.

Molife LR, Rudman SM, Alam S, Tan DS, Kristeleit H, Middleton G, Propper D, Bent L, Stopfer P, Uttenreuther-Fischer M, Wallenstein G, de Bono J, Spicer J.

Cancer Chemother Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article · DOI 10.1007/s00280-013-2286-7

Bibliografisk träff 2013-09-01

Afatinib: first global approval.

Dungo RT, Keating GM.

Drugs · review; journal article · DOI 10.1007/s40265-013-0111-6

Bibliografisk träff 2013-07-01

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M.

J Clin Oncol · clinical trial, phase iii; multicenter study; randomized controlled trial; journal article · DOI 10.1200/jco.2012.44.2806

Bibliografisk träff 2013-07-01

Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations.

Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV.

J Clin Oncol · clinical trial, phase iii; research support, non-u.s. gov't; randomized controlled trial; journal article · DOI 10.1200/jco.2012.46.1764

Bibliografisk träff 2013-05-10

Clinical perspective of afatinib in non-small cell lung cancer.

Chen X, Zhu Q, Zhu L, Pei D, Liu Y, Yin Y, Schuler M, Shu Y.

Lung Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.lungcan.2013.02.021

Bibliografisk träff 2013-04-11

Monitoring afatinib treatment in HER2-positive gastric cancer with 18F-FDG and 89Zr-trastuzumab PET.

Janjigian YY, Viola-Villegas N, Holland JP, Divilov V, Carlin SD, Gomes-DaGama EM, Chiosis G, Carbonetti G, de Stanchina E, Lewis JS.

J Nucl Med · research support, non-u.s. gov't; research-article; journal article · DOI 10.2967/jnumed.112.110239

Bibliografisk träff 2013-03-18

Dermatologic adverse events associated with afatinib: an oral ErbB family blocker.

Lacouture ME, Schadendorf D, Chu CY, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Hauschild A.

Expert Rev Anticancer Ther · research support, non-u.s. gov't; review; journal article · DOI 10.1586/era.13.30

Bibliografisk träff 2013-02-26

Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.

Ninomiya T, Takigawa N, Ichihara E, Ochi N, Murakami T, Honda Y, Kubo T, Minami D, Kudo K, Tanimoto M, Kiura K.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-12-0885

Bibliografisk träff 2013-01-04

A phase Ib, open-label study to assess the safety of continuous oral treatment with afatinib in combination with two chemotherapy regimens: cisplatin plus paclitaxel and cisplatin plus 5-fluorouracil, in patients with advanced solid tumors.

Vermorken JB, Rottey S, Ehrnrooth E, Pelling K, Lahogue A, Wind S, Machiels JP.

Ann Oncol · research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1093/annonc/mds633

Bibliografisk träff 2012-11-17

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.

Awada AH, Dumez H, Hendlisz A, Wolter P, Besse-Hammer T, Uttenreuther-Fischer M, Stopfer P, Fleischer F, Piccart M, Schöffski P.

Invest New Drugs · research support, non-u.s. gov't; research-article; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s10637-012-9880-0

Bibliografisk träff 2012-11-17

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors.

Marshall J, Hwang J, Eskens FA, Burger H, Malik S, Uttenreuther-Fischer M, Stopfer P, Ould-Kaci M, Cohen RB, Lewis NL.

Invest New Drugs · research support, non-u.s. gov't; research-article; clinical trial, phase i; journal article · DOI 10.1007/s10637-012-9890-y

Bibliografisk träff 2012-08-10

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR.

J Pharmacol Exp Ther · research support, non-u.s. gov't; journal article · DOI 10.1124/jpet.112.197756

Bibliografisk träff 2012-07-05

A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.

Schuler M, Awada A, Harter P, Canon JL, Possinger K, Schmidt M, De Grève J, Neven P, Dirix L, Jonat W, Beckmann MW, Schütte J, Fasching PA, Gottschalk N, Besse-Hammer T, Fleischer F, Wind S, Uttenreuther-Fischer M, Piccart M, Harbeck N.

Breast Cancer Res Treat · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1007/s10549-012-2126-1

Bibliografisk träff 2012-03-15

A phase II study of afatinib (BIBW 2992), an irreversible ErbB family blocker, in patients with HER2-positive metastatic breast cancer progressing after trastuzumab.

Lin NU, Winer EP, Wheatley D, Carey LA, Houston S, Mendelson D, Munster P, Frakes L, Kelly S, Garcia AA, Cleator S, Uttenreuther-Fischer M, Jones H, Wind S, Vinisko R, Hickish T.

Breast Cancer Res Treat · clinical trial, phase ii; research support, non-u.s. gov't; research-article; multicenter study; journal article · DOI 10.1007/s10549-012-2003-y

Bibliografisk träff 2012-02-10

Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.

De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In't Veld P, Schallier D.

Lung Cancer · research support, non-u.s. gov't; journal article; case reports · DOI 10.1016/j.lungcan.2012.01.008

Bibliografisk träff 2012-01-17

Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence.

Ou SH.

Crit Rev Oncol Hematol · research support, non-u.s. gov't; review; journal article · DOI 10.1016/j.critrevonc.2011.11.010

Bibliografisk träff 2011-12-27

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers.

Stopfer P, Marzin K, Narjes H, Gansser D, Shahidi M, Uttereuther-Fischer M, Ebner T.

Cancer Chemother Pharmacol · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1007/s00280-011-1803-9

Bibliografisk träff 2011-11-10

Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).

Murakami H, Tamura T, Takahashi T, Nokihara H, Naito T, Nakamura Y, Nishio K, Seki Y, Sarashina A, Shahidi M, Yamamoto N.

Cancer Chemother Pharmacol · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; clinical trial, phase i; journal article · DOI 10.1007/s00280-011-1738-1

Bibliografisk träff 2011-10-17

Current and emerging targeted therapies for metastatic breast cancer.

Perez EA, Spano JP.

Cancer · research support, non-u.s. gov't; review; journal article · DOI 10.1002/cncr.26356

Bibliografisk träff 2011-07-01

Afatinib (BIBW 2992) development in non-small-cell lung cancer.

Hirsh V.

Future Oncol · journal article · DOI 10.2217/fon.11.62

Bibliografisk träff 2011-06-01

Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.

Bouche O, Maindrault-Goebel F, Ducreux M, Lledo G, Andre T, Stopfer P, Amellal N, Merger M, De Gramont A.

Anticancer Res · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; journal article